Objective: To evaluate the sedative effects of a combination of sufentanil and midazolam administered intramuscularly (IM) or intranasally (IN) prior to induction of anesthesia with propofol in New Zealand White rabbits.
Study Design: Prospective, randomized, crossover, experimental study.
Animals: A total of 11 adult New Zealand White rabbits.
Methods: Sufentanil (0.5 μg kg) and midazolam (2 mg kg) were administered to rabbits via IM or IN route. The righting reflex was assessed, and sedation was scored. Heart rate, respiratory rate (f) and temperature were recorded prior to treatment administration and after loss of the righting reflex.
Results: Measured variables remained within normal physiologic ranges for all rabbits. The only statistically significant change was for f, which was significantly lower after sedation for both routes. The time to loss of righting reflex was 14.8 ± 6.5 and 12.5 ± 7.4 minutes and sedation scores were 6 (4-8) and 7 (6-8) for IM and IN routes, respectively, with no difference between treatments. No adverse effects were observed during the experimental period.
Conclusions And Clinical Relevance: Sufentanil combined with midazolam administered either IM or IN resulted in moderate to deep sedation in New Zealand White rabbits at the dose rates studied.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaa.2022.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
Lancet
January 2025
British Heart Foundation Centre of Research Excellence, University of Edinburgh, Edinburgh, UK; Edinburgh Imaging, University of Edinburgh, Edinburgh, UK.
Background: The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in management and outcomes.
Methods: SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from 12 outpatient cardiology chest pain clinics across Scotland.
Establishment and Evaluation of Rabbit Model for Corneal Ectasia by Photorefractive Keratectomy.
Exp Eye Res
January 2025
Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
The study aimed to compare the effects of different types of excimer laser keratectomy on rabbit corneas and to identify the optimal disease model for corneal ectasia. Additionally, investigating the structural and molecular alterations in the novel disease model helped explore the mechanisms underlying biomechanical cues in corneal ectasia. 2.
View Article and Find Full Text PDFCombination of HSP90 Inhibitors and HSP70 Inducers Prevent Hydrochloric Acid-Induced Pulmonary Fibrosis in Rabbits.
Int J Mol Sci
January 2025
Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23508, USA.
Combined therapies with Heat Shock Protein 90 (HSP90) inhibitors and Heat Shock Protein 70 (HSP70) inducers are gaining significant interest in cancer and cardiovascular research. Here, we tested the hypothesis that HSP90 inhibitors and HSP70 inducers, together, can block the development of pulmonary fibrosis. We exposed New Zealand White Rabbits to hydrochloric acid (HCl, 0.
View Article and Find Full Text PDFIntroduction: Around the world, rates of induction of labour (IOL) among nulliparous mothers have increased in the last 10 years. In Australia, rates have increased over the last decade by 43%, from 32% to 46%. There is growing concern about the rapid rise in IOL before 41 weeks for nulliparous women without medical complications because of the associated increased rates of caesarean section, reduced satisfaction with birth, and birth trauma.
View Article and Find Full Text PDFBackground: PD-L1 and VEGF blockade with atezolizumab plus bevacizumab has been shown to improve survival in unresectable hepatocellular carcinoma. TIGIT is an immune checkpoint regulator implicated in many cancers, including unresectable hepatocellular carcinoma. Here, we evaluate the clinical activity and safety of the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab plus bevacizumab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!